Group 1 - The core viewpoint is that pharmaceutical stocks, particularly Bristol-Myers Squibb, are experiencing depressed valuations, which seem to have become the new normal [1] - Bristol-Myers Squibb's forward price-to-earnings multiple has declined further since the Q3 2024 analysis, indicating a negative trend in its valuation [1]